SCHEMBL6326103

SCHEMBL6326103

CN(C)C(=O)[C@@H](Cc1ccccc1)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 1/20 0.45
MMP13 P45452 1/20 0.45
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
MMP14 P50281 1/20 0.43
ATM Q13315 1/20 0.42
ITGA4 P13612 1/20 0.42
ITGB7 P26010 1/20 0.42
HPGD P15428 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
CTSS P25774 2/20 0.41
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
CTSK P43235 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
ACE P12821 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
AKT1 P31749 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30688551 0.89 ITGB3 (0.45) RENMMP13MMP9ATMITGA4
SCHEMBL30688558 0.89 ITGB3 (0.45) RENMMP13MMP9ATMITGA4
SCHEMBL3268338 0.89 REN (0.44) RENMMP13ATMITGA4ITGB7
SCHEMBL22457743 0.89 ITGB3 (0.45) RENMMP13MMP9ATMITGA4
SCHEMBL1401042 0.89 MMP13 (0.46) RENMMP13MMP9ATMITGA4
SCHEMBL2476924 0.89 MMP13 (0.46) RENMMP13MMP9ATMITGA4
SCHEMBL65502 0.89 MMP13 (0.46) RENMMP13MMP9ATMITGA4
SCHEMBL24435948 0.88 NPY5R (0.45) RENMMP13ATMITGA4ITGB7
SCHEMBL24443521 0.88 REN (0.45) RENMMP13ATMITGA4ITGB7
SCHEMBL6317705 0.88 GHSR (0.48) RENMMP13MMP9MMP8CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 REN 261/4885MMP13 2217/4885MMP9 2831/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR REN 263/4885MMP13 2288/4885MMP9 3090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.